1. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN7–14 and Antagonist RM26
   Siyuan Cheng et al, 2018, Bioconjugate Chem. CrossRef
2. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
   Sara S. Rinne et al, 2019, Sci Rep CrossRef
3. Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu‐DOTAGA‐PEG 2 ‐RM26
   Bogdan Mitran et al, 2019, Int. J. Cancer CrossRef
4. Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
   Maryam Oroujeni et al, 2019, Pharmaceutics CrossRef
5. Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology
   Theodosia Maina et al, 2017, PET Clinics CrossRef
6. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
   Bogdan Mitran et al, 2019, Sci Rep CrossRef
7. tBu4octapa-alkyl-NHS for metalloradiopeptide preparation
   Lily Li et al, 2020, Dalton Trans. CrossRef
8. Surface Charge of Supramolecular Nanosystems for In Vivo Biodistribution: A MicroSPECT/CT Imaging Study
   Ling Ding et al, 2020, Small CrossRef
9. Synthesis and Evaluation of a Macrocyclic Actinium‐225 Chelator, Quality Control and In Vivo Evaluation of 225 Ac‐crown‐αMSH Peptide
   Hua Yang et al, 2020, Chem. Eur. J. CrossRef
10. Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
    Ayman Abouzayed et al, 2020, Pharmaceutics CrossRef
11. New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer
    Xin Li et al, 2020, Front. Chem. CrossRef
12. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
    Christina Baun et al, 2020, Molecules CrossRef
13. The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer
    Chul-Hee Lee et al, 2021, Cancer Biotherapy and Radiopharmaceuticals CrossRef
14. 66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26
    Sara S. Rinne et al, 2021, Sci Rep CrossRef
15. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
    Sara S. Rinne et al, 2021, IJMS CrossRef
16. Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer
    Julia Baguña Torres et al, 2020, J Nucl Med CrossRef
17. Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with 68Ga-Labeled Antagonists: The Chelate Makes the Difference Again
    Emma Renard et al, 2021, J. Med. Chem. CrossRef
18. Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties
    Bogdan Mitran et al, 2020, CMC CrossRef
19. PET/Fluorescence Imaging: An Overview of the Chemical Strategies to Build Dual Imaging Tools
    Julen Ariztia et al, 2022, Bioconjugate Chem. CrossRef
20. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals
    Jens Kurth et al, 2022, Nuklearmedizin CrossRef
21. Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications
    Daniel Kwon et al, 2022, Pharmaceutics CrossRef
22. The effects of novel macrocyclic chelates on the targeting properties of the 68Ga-labeled Gastrin releasing peptide receptor antagonist RM2
    Yinwen Wang et al, 2023, EJNMMI Res CrossRef
23. Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer
    Christina Baun et al, 2023, Sci Rep CrossRef
24. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
    Panagiotis Kanellopoulos et al, 2024, EJNMMI radiopharm. chem. CrossRef
25. Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands
    Kim E. de Roode et al, 2024, Pharmaceuticals CrossRef
26. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management
    Simone Dalm et al, 2024, PET Clinics CrossRef